There were 40 trials of concurrent choice acquisition training in total.
Double blind, parallel group studies remain the trial design of choice, but incorporation of validated outcome assessments and measurement of potential confounders of treatment response need attention in future trials.
While a prospective gathering of data would have probably influenced our attitude in favour of de-escalation, it would be the clinical trial design of choice to answer the question of de-escalation efficiency.
The trial-by-trial sequence of choices for each subject was fit by a simple Rescorla-Wagner (RW) model in which behavior is driven by the expectation of rewards and in which trial-by-trial behavioral adaptation is proportional to the difference between the expected and obtained rewards [ 7].
Issues of importance in these smaller trials include choice of agent, selection of appropriate trial participants, trial design, method of access to breast tissue in women without cancer, selection and monitoring of SEBs, and monitoring of drug toxicity.
In a daily experimental session, rats executed four blocks of 10 trials of a spatial choice task in the four-arm radial maze.
Due to a lack of adequate randomized trials, the choice of clinical or surgical treatment remains based on the description of a clinical series of cases.
After a variable number of choice trials the reward locations were shuffled and animals had to disengage from the now devalued arm and explore the other options in order to optimise payout.
We focused on replay events occurring at forced reward locations, which represent the beginning of choice trials and which comprised the majority of replay events (703/876, 80.3%; compared to 173 at choice reward locations).
Here we fit the model to a lexical decision data set featuring 39 participants who each completed 28,074 trials of speeded two-choice decisions (Keuleers, Brysbaert, & New, 2010).
